TransCode Therapeutics Inc (NASDAQ:RNAZ) shares traded 2.86% higher at $0.37 on Wall Street last session.
In accordance with the data, 1 analysts cover TransCode Therapeutics Inc (NASDAQ:RNAZ). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $3.00 and a low of $3.00, we find $3.00. Given the previous closing price of $0.36, this indicates a potential upside of 733.33 percent. RNAZ stock price is now -56.34% away from the 50-day moving average and -92.56% away from the 200-day moving average. The market capitalization of the company currently stands at $1.33M.
It has been rated a hold by 0 analysts and a buy by 1. Brokers who have rated the stock have averaged $3.00 as their price target over the next twelve months.
In other news, Dudley Robert Michael, Chief Executive Officer bought 98,000 shares of the company’s stock on Sep 28. The stock was bought for $49,980 at an average price of $0.51. Upon completion of the transaction, the Chief Executive Officer now directly owns 180,262 shares in the company, valued at $66696.94. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 28, Chief Financial Officer Fitzgerald Thomas A bought 49,350 shares of the business’s stock. A total of $25,168 was incurred on buying the stock at an average price of $0.51. This leaves the insider owning 56,318 shares of the company worth $20837.66. A total of 11.02% of the company’s stock is owned by insiders.
TransCode Therapeutics Inc (NASDAQ: RNAZ) opened at $0.4000 on Tuesday. During the past 12 months, TransCode Therapeutics Inc has had a low of $0.28 and a high of $23.40. As of last week, the company has a debt-to-equity ratio of 0.32, a current ratio of 1.39, and a quick ratio of 1.39. The fifty day moving average price for RNAZ is $0.8224 and a two-hundred day moving average price translates $4.9167 for the stock.
The latest earnings results from TransCode Therapeutics Inc (NASDAQ: RNAZ) was released for Jun, 2023.
TransCode Therapeutics Inc(RNAZ) Company Profile
TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
